Identification of a Unique Antigen Peptide PRL1 on BALB/c RL Male 1 Leukemia Recognized by Cytotoxic T Lymphocytes and Its Relation to the Akt Oncogene

Overview

Journal J Exp Med

Specialties Allergy & Immunology
General Medicine

Date 1994 Nov 1

PMID 7964448

Citations 30

Authors

A Uenaka

T Ono

T Akisawa

H Wada

T Yasuda

E Nakayama

Affiliations

Soon will be listed here.

Abstract

BALB/c radiation leukemia RL male 1 is an immunogenic tumor. We established bulk and cloned cytotoxic T lymphocyte (CTL) lines from regressor (BALB/c x C57BL/6)F1 (CB6F1) spleen cells that recognized RL male 1 specifically. We then obtained antigen peptide recognized by CTL from RL male 1 by acid extraction. Analysis of the acid extract by reversed-phase high performance liquid chromatography (HPLC) on a semipreparative C18 column revealed that fractions eluted in 23 min (peak a) and 26 min (peak b) showed sensitization activity on the P815 target for specific CTL. On further purification of these fractions by HPLC and direct sequencing by Edman degradation, we identified the CTL-recognizing RL male 1 peptide pRL1a (IPGLPLSL) in peak a and its possible precursor peptide pRL1b (SIIPGLPLSL) in peak b. Sequence homology indicated that these peptides were derived from the 5' untranslated region of c-akt oncogene.

Citing Articles

The landscape of T cell antigens for cancer immunotherapy.

Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y Nat Cancer. 2023; 4(7):937-954.

PMID: 37415076 DOI: 10.1038/s43018-023-00588-x.

Toward Establishing an Ideal Adjuvant for Non-Inflammatory Immune Enhancement.

Seya T, Tatematsu M, Matsumoto M Cells. 2022; 11(24).

PMID: 36552770 PMC: 9777512. DOI: 10.3390/cells11244006.

Understanding small ORF diversity through a comprehensive transcription feature classification.

Guerra-Almeida D, Tschoeke D, Nunes-da-Fonseca R DNA Res. 2021; 28(5).

PMID: 34240112 PMC: 8435553. DOI: 10.1093/dnares/dsab007.

Antitumour dendritic cell vaccination in a priming and boosting approach.

Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft L Nat Rev Drug Discov. 2020; 19(9):635-652.

PMID: 32764681 DOI: 10.1038/s41573-020-0074-8.

Comprehensive profiling of translation initiation in influenza virus infected cells.

Machkovech H, Bloom J, Subramaniam A PLoS Pathog. 2019; 15(1):e1007518.

PMID: 30673779 PMC: 6361465. DOI: 10.1371/journal.ppat.1007518.

References

Traversari C, van der Bruggen P, Luescher I, Lurquin C, Chomez P, Van Pel A . A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med. 1992; 176(5):1453-7. PMC: 2119413. DOI: 10.1084/jem.176.5.1453. View

Dunn T, Potter M . A transplantable mast-cell neoplasm in the mouse. J Natl Cancer Inst. 1957; 18(4):587-601. View

Sherman L, Burke T, Biggs J . Extracellular processing of peptide antigens that bind class I major histocompatibility molecules. J Exp Med. 1992; 175(5):1221-6. PMC: 2119214. DOI: 10.1084/jem.175.5.1221. View

van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B . A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254(5038):1643-7. DOI: 10.1126/science.1840703. View

Udono H, Mieno M, Shiku H, Nakayama E . The roles of CD8+ and CD4+ cells in tumor rejection. Jpn J Cancer Res. 1989; 80(7):649-54. PMC: 5917808. DOI: 10.1111/j.1349-7006.1989.tb01692.x. View

Greenberg P . Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991; 49:281-355. DOI: 10.1016/s0065-2776(08)60778-6. View

Rosenberg A, Mizuochi T, Sharrow S, Singer A . Phenotype, specificity, and function of T cell subsets and T cell interactions involved in skin allograft rejection. J Exp Med. 1987; 165(5):1296-315. PMC: 2188316. DOI: 10.1084/jem.165.5.1296. View

Skipper J, Stauss H . Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J Exp Med. 1993; 177(5):1493-8. PMC: 2190995. DOI: 10.1084/jem.177.5.1493. View

Margulies D, Evans G, Ozato K, Camerini-Otero R, Tanaka K, Appella E . Expression of H-2Dd and H-2Ld mouse major histocompatibility antigen genes in L cells after DNA-mediated gene transfer. J Immunol. 1983; 130(1):463-70. View

10.

Klein G, Sjogren H, Klein E, Hellstrom K . Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960; 20:1561-72. View

11.

Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B . The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993; 178(2):489-95. PMC: 2191123. DOI: 10.1084/jem.178.2.489. View

12.

Joyce S, Tabaczewski P, Angeletti R, Nathenson S, Stroynowski I . A nonpolymorphic major histocompatibility complex class Ib molecule binds a large array of diverse self-peptides. J Exp Med. 1994; 179(2):579-88. PMC: 2191392. DOI: 10.1084/jem.179.2.579. View

13.

Watanabe M, Suzuki T, Taniguchi M, Shinohara N . Monoclonal anti-Ia murine alloantibodies crossreactive with the Ia-homologues of other mammalian species including humans. Transplantation. 1983; 36(6):712-8. DOI: 10.1097/00007890-198336060-00025. View

14.

Ahmed N, Franke T, Bellacosa A, Datta K, Taguchi T, Testa J . The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene. 1993; 8(7):1957-63. View

15.

van Bleek G, Nathenson S . Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature. 1990; 348(6298):213-6. DOI: 10.1038/348213a0. View

16.

Bishop J . Molecular themes in oncogenesis. Cell. 1991; 64(2):235-48. DOI: 10.1016/0092-8674(91)90636-d. View

17.

Bellacosa A, Testa J, Staal S, Tsichlis P . A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science. 1991; 254(5029):274-7. DOI: 10.1126/science.254.5029.274. View

18.

Nakayama E, Uenaka A . Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med. 1985; 161(2):345-55. PMC: 2187571. DOI: 10.1084/jem.161.2.345. View

19.

Henderson R, Cox A, Sakaguchi K, Appella E, Shabanowitz J, Hunt D . Direct identification of an endogenous peptide recognized by multiple HLA-A2.1-specific cytotoxic T cells. Proc Natl Acad Sci U S A. 1993; 90(21):10275-9. PMC: 47757. DOI: 10.1073/pnas.90.21.10275. View

20.

Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer zum Buschenfelde K . Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol. 1994; 24(3):759-64. DOI: 10.1002/eji.1830240340. View